Skip to main content

Table 2 Drug survival of the second JAK inhibitor

From: Drug survival and change of disease activity using a second janus kinase inhibitor in patients with difficult-to-treat rheumatoid arthritis who failed to a janus kinase inhibitor and subsequent biologics

 

N = 32

Duration of the second JAKi exposure, months, median (IQR)

13.5 (4.5, 23.8)

Discontinuation of the second JAKi, n (%)

20 (62.5)

Time to discontinuation of the second JAKi, months, median (IQR)

9.0 (3.3, 13.8)

Reasons for discontinuation of the second JAKi, n (%)

Primary failure

9 (45.0)

Secondary failure

5 (25.0)

Adverse events

2 (10.0)

Insurance coverage issues

4 (20.0)

  1. JAKi, Janus kinase inhibitor
Back to article page

Advances in Rheumatology

ISSN: 2523-3106